December 22, 2017 / 10:29 PM / a year ago

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

Dec 22 (Reuters) - Portola Pharmaceuticals Inc:

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

* PORTOLA PHARMACEUTICALS - U.S. FDA WILL EXTEND REVIEW OF BIOLOGICS LICENSE APPLICATION FOR ANDEXXA (ANDEXANET ALFA) BY 90 DAYS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below